Compare RWAY & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RWAY | NERV |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 226.3M | 210.1M |
| IPO Year | N/A | 2014 |
| Metric | RWAY | NERV |
|---|---|---|
| Price | $5.45 | $4.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 2 |
| Target Price | $9.50 | ★ $10.50 |
| AVG Volume (30 Days) | ★ 646.1K | 358.2K |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | ★ 21.54% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,175,600.00 |
| Revenue This Year | $1.26 | N/A |
| Revenue Next Year | $1.25 | N/A |
| P/E Ratio | $5.70 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.19 | $1.76 |
| 52 Week High | $11.20 | $12.46 |
| Indicator | RWAY | NERV |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Runway Growth Finance Corp is a specialty finance company focused on providing senior secured loans to high-growth-potential companies in technology, life sciences, healthcare information and services, business services, select consumer services and products, and other high-growth industries. The company has Investments in the United States, Germany, and UK, Canada, Netherlands, with the majority of its portfolio invested in the United States. The company's investment objective is to maximize its total return to its stockholders through current income on its loan portfolio, and secondarily through capital gain on its warrants and other equity positions.
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.